At 24.0% CAGR, Asia Pacific Organoids Services Market is Projected to be Worth US$ 2,327.10 Million by 2031, says Business Market Insights

According to Business Market Insights research, the Asia Pacific organoids services market was valued at US$ 515.83 million in 2024 and is expected to reach US$ 2,327.10 million by 2031, registering a CAGR of 24.0% from 2024 to 2031. Surge in popularity of personalized drugs and increasing key developments are among the critical factors attributed to driving the Asia Pacific organoids services market growth.

Across Asia, the rise of personalized medicine is significantly accelerating the development and implementation of organoid technologies. In China, companies such as ACCURATE International Biotechnology have established one of the world’s largest tumor organoid platforms, which houses over 5,000 models to support patient-specific drug testing. Collaborative laboratories launched in 2022 with leading institutions like the University of Macau have further enhanced research on disease modeling and drug responses. Further, in Japan, universities such as Kyushu and Nagoya have integrated artificial intelligence with organoid development, achieving up to 70% accuracy in selecting high-quality organoids for therapeutic use. Japanese researchers are also investigating gene-edited organoids to study liver and neurological disorders. In South Korea, the 2024 Organoid Developer Conference held in Pangyo showcased applications in regenerative medicine, with experts such as Dr. Ryuichi Okamoto discussing the use of organoids in treating ulcerative colitis. Meanwhile, Singapore is emerging as a regional hub for innovation. In 2024, Next&Bio signed a memorandum of understanding with the Cancer Science Institute of Singapore to co-develop a cancer organoid bank, which will enable more effective, patient-matched oncology therapies. These national initiatives reflect a broader regional commitment to integrating organoids into precision healthcare systems. As a result, organoid services across Asia are rapidly evolving essential tools for personalized diagnostics, drug screening, and disease modeling, transforming both research and clinical practice into the process.

On the contrary, the dearth of skilled professionals hampers the growth of the Asia Pacific organoids services market.

By type, the Asia Pacific organoids services market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine held 23.0% share of Asia Pacific Organoids Services Market share in 2024, amassing US$ 118.81 million. It is projected to garner US$ 527.37 million by 2031 to register 23.7% CAGR during 2024–2031.

By application, the Asia Pacific organoids services market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology disease held 29.9% share of Asia Pacific organoids services market share in 2024, amassing US$ 154.25 million. It is projected to garner US$ 724.06 million by 2031 to register 24.7% CAGR during 2024–2031.

By source, the Asia Pacific organoids services market is bifurcated into pluripotent stem cells and organ specific adult stem cell. The pluripotent stem cells held 72.8% share of Asia Pacific organoids services market share in 2024, amassing US$ 375.56 million. It is projected to garner US$ 1,740.82 million by 2031 to register 24.5% CAGR during 2024–2031

Based on country, the Asia Pacific organoids services market is categorized into Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 28.0% share of Asia Pacific organoids services market in 2024. It was assessed at US$ 144.17 million in 2024 and is likely to hit US$ 627.62 million by 2031, registering a CAGR of 23.4% during 2024–2031.

Key players operating in the organoids services market are CUSABIO TECHNOLOGY LLC; Cyprio; Eurofins Scientific SE; HUB Organoids B.V. (Hubrecht Organoid Technology); InnoSer; InSphero; LABTOO; Molecular Devices, LLC.; Oncodesign Services; and Sino Biological Inc., among others.

• In May 2024: InSphero AG is pleased to announce its exclusive commercialization partnership with Genome Biologics, based in Frankfurt, Germany. This partnership will grant InSphero exclusive global rights to commercialize Genome Biologics' revolutionary 3D Cardiac Organoid Platform. This platform is at the forefront of cardiac disease research, offering precise, scalable, and disease-specific organoid models that are crucial for the development of novel therapeutics.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com